Germany health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 5 of 33 of this archive, newest first.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
Efficacy was never the question in this appraisal. Duration of treatment was.
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.